Introduction
The main focus of the Bettelli Lab is to identify the cell types of the immune system and mechanisms, which induce and regulate the development of autoimmunity.
Member
Estelle Bettelli, PhD
Member, Fundamental Immunology Program; Principal Investigator, Bettelli Lab; Affiliated Professor, UW Department of Immunology
View Full Bio
Lab Members
Pushpa Palle, PhD
Post Doctoral Research Associate, Bettelli Lab
Yevgeniy Yuzefpolskiy, PhD
Post Doctoral Research Associate, Bettelli Lab
Featured Publications
May 2022
STAT1 signaling protects self-reactive T cells from control by innate cells during neuroinflammation.
Arbelaez CA, Palle P, Charaix J, Bettelli E
Mar 2022
Cutting Edge: Effect of Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Immune Responses in Multiple Sclerosis Patients.
Yuzefpolskiy Y, Morawski P, Fahning M, Speake C, Lord S, Chaudhary A, Morishima C, Wener MH, Kita M, McCarthy L, Buckner JH, Campbell DJ, Bettelli E
Nov 2021
Cutting Edge: DOCK8 Regulates a Subset of Dendritic Cells That Is Critical for the Development of Experimental Autoimmune Encephalomyelitis.
Weliwitigoda A, Palle P, Gessner M, Hubbard NW, Oukka M, Bettelli E
Oct 2020
Circulating TFH cells as a marker for early therapeutic intervention in T1D.
Bettelli E, Campbell DJ
Mar 2019
Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance.
Glatigny S, Höllbacher B, Motley SJ, Tan C, Hundhausen C, Buckner JH, Smilek D, Khoury SJ, Ding L, Qin T, Pardo J, Nepom GT, Turka LA, Harris KM, Campbell DJ, Bettelli E
June 30, 2023
What Do T Cells Like to Eat? The Answer Could Stop Multiple Sclerosis
Cells, like people, get their energy from sugars, proteins and fats. Many cells have highly specialized diets — think of some loving kale while others prefer Texas BBQ.
June 17, 2022
Do MS Treatments Make Vaccines Less Effective?
This issue of vaccine efficacy has taken center stage in light of the pandemic. A BRI team led by Estelle Bettelli, PhD, and Yevgeniy Yuzefpolskiy, PhD, recently made key findings about how three different medicines for multiple sclerosis (MS) impact response to COVID-19 vaccines.
September 11, 2020
Taking on Multiple Sclerosis
Dr. Bettelli’s team develops sophisticated MS models to investigate its mysteries and pursue innovative therapies. We recently asked her for an update on BRI’s MS progress.
Benaroya Research Institute Awarded $11.4 M NIH U19 Grant to Profile Respiratory Viral Infections in Vulnerable Populations and $3.9M NIH R01 Grant to Develop New Treatments for Type 1 Diabetes
Read More
Benaroya Research Institute Team Examines COVID Vaccine Response in People Under Treatment for MS and Other Autoimmune Diseases
Read More
